In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Executive Summary

Merck's takeout of Sirna gives a boost to platform biotech investors and has allowed Merck to stake an expansive claim in RNAi. The deal caps a massive turnaround for Sirna--previously Ribozyme Pharmaceuticals--and rewards the investors who took an early chance on RNAi therapies. The move should pay off handsomely for Merck, now the leader in RNAi, provided the technology turns out to be the next Antibodies, not the next Antisense.
Advertisement

Related Content

Roche Exits RNAi, Raising Questions For Stalwarts
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Finding a Way Out of Pharma's Dealmaking Dilemma
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
The Heyday of Biotech Dealmaking
Visible Progress in Devices for Age-Related Macular Degeneration
Deal Statistics Quarterly, Q4 2006
Ophthalmology's Next Frontier
A Look Back at 2006: The Pipeline Challenge
The Large Molecule Future

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel